Medical update - New treatment for dry macular degeneration on the horizon
Dry macular degeneration, also known as atrophic AMD, is the more common form of macular degeneration (MD) and a frequent cause of vision loss in older adults. Traditional treatment options for dry MD have been limited, mostly centred on prevention and supportive measures, such as low vision aids, diet and nutrition.
However, a new approach using pegcetacoplan, known as Syfovre, has emerged as a potential breakthrough in managing this condition.
This new drug, intravitreal pegcetacoplan, represents a novel and innovative approach to treating dry MD. By directly targeting the alternative pathway of the complement system, this therapy aims to reduce inflammation and damage to the macula.
Like other treatments for MD, pegcetacoplan is an injection in the eye, given either 4 or 8 weekly. Clinical trials evaluating intravitreal pegcetacoplan have shown promising results. The phase 2 FILLY study and the phase 3 studies OAKS and DERBY confirmed that pegcetacoplan reduced the rate of progression of late MD. Additionally, improvements in visual function and quality of life were observed. These findings provide evidence of the potential benefits of intravitreal pegcetacoplan in slowing disease progression and preserving vision in patients with dry MD.
While further research and clinical trials are needed to establish its long-term efficacy and safety, intravitreal pegcetacoplan holds promise for individuals affected by dry macular degeneration, offering hope for improved outcomes and vision preservation.
The drug has recently been approved for use in the USA (Nov 2022) and is currently being tested at trial sites in Australia. In NZ all medicines must first gain approval from Medsafe, to ensure the medicine is safe, appropriate and effective. Then Pharmac evaluate the medicine to determine if it will be publicly funded. Pegcetacoplan has not undergone either of these reviews in New Zealand at present, so it will be a while until it is available here. We will keep you posted.
